Ameritas Investment Partners’s Outlook Therapeutics OTLK Stock Holding History

Ameritas Investment Partners’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-607	Closed	-$741	–	3303
2025 Q1	$741	Hold	607	–	–	﹤0.01%	3113
2024 Q4	$1.15K	Hold	607	–	–	﹤0.01%	3116
2024 Q3	$3.24K	Hold	607	–	–	﹤0.01%	3078
2024 Q2	$4.48K	Hold	607	–	–	﹤0.01%	3042
2024 Q1	$7.25K	Hold	607	–	–	﹤0.01%	2895
2023 Q4	$4.79K	Hold	607	–	–	﹤0.01%	2973
2023 Q3	$2.68K	Hold	607	–	–	﹤0.01%	3049
2023 Q2	$21.1K	Buy	607 +264	+77%	+$7.2K	﹤0.01%	2536
2023 Q1	$7.49K	Hold	343	–	–	﹤0.01%	2800
2022 Q4	$7.55K	Hold	343	–	–	﹤0.01%	2864
2022 Q3	$8K	Hold	343	–	–	﹤0.01%	2859
2022 Q2	$7K	Hold	343	–	–	﹤0.01%	2914
2022 Q1	$12K	Hold	343	–	–	﹤0.01%	2742
2021 Q4	$9K	Hold	343	–	–	﹤0.01%	2928
2021 Q3	$15K	Hold	343	–	–	﹤0.01%	2823
2021 Q2	$17K	Buy	+343	New	+$15.9K	﹤0.01%	2818

Other funds holding OTLK

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameritas Investment Partners's OTLK Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Outlook Therapeutics (OTLK) in Q2 2025, closing a stake of 607 shares — an estimated $741 sold.

Ameritas Investment Partners first reported a position in OTLK in Q2 2021 and held it in 16 quarters. The position peaked at $21.1K in Q2 2023. 66 funds tracked by Wall St. Rank hold OTLK as of Q2 2025.

Ameritas Investment Partners reported no remaining Outlook Therapeutics position as of Q2 2025 after selling out during the quarter.
Ameritas Investment Partners sold 607 Outlook Therapeutics shares in Q2 2025, an estimated $741.
Ameritas Investment Partners first reported a position in Outlook Therapeutics in Q2 2021 and held it in 16 quarters.
Ameritas Investment Partners's Outlook Therapeutics position peaked at $21.1K in Q2 2023.
66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.